EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal
Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus Cambridge, 23rd June 2022: Transine Therapeutics